Analyst Julian Harrison of BTIG maintained a Buy rating on Ardelyx, retaining the price target of $14.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Julian Harrison has given his Buy rating due to a combination of factors that highlight Ardelyx’s potential for growth and market positioning. The anticipated growth in Ibsrela’s revenue is a significant factor, with expectations of a 21% increase from the previous quarter and strong growth projected for the rest of the year. This growth trajectory is supported by the achievable $1 billion peak net sales target, which appears conservative given the current market conditions and Ibsrela’s unique position as the only non-secretagogue treatment option.
Additionally, the market opportunity for Ibsrela is bolstered by the fact that up to 50% of IBS-C patients do not respond adequately to existing treatments, leaving a gap that Ibsrela can fill. Furthermore, Xphozah presents an attractive alternative to current phosphate binders, which have a high pill burden, potentially improving patient adherence. The valuation of Ardelyx using a discounted cash flow analysis further supports the Buy rating, indicating a favorable long-term financial outlook for the company.
In another report released on July 22, TD Cowen also maintained a Buy rating on the stock with a $9.00 price target.
Based on the recent corporate insider activity of 77 insiders, corporate insider sentiment is neutral on the stock.